Financing channel feed – Endpoints News

Financing channel feed

Zealand rides obesity wave with $1B raise to advance amylin drug and look for a partner

10 months ago

Exclusive: Cityblock Health investors buy employee shares in tender offer

10 months ago

New cancer biotech emerges from Stanford research, with help of Nobel laureate Carolyn Bertozzi

10 months ago

Ex-Meta scientists launch EvolutionaryScale with $142M seed round, unveiling next-gen AI model for protein design

10 months ago

Can mRNA be harnessed for gene insertion? Moderna's former chief medical officer has $82M to find out

10 months ago

Grail prepares for public debut, and challenges of going independent, after spinoff from Illumina

10 months ago

Commercial-stage blood cancer biotech files for US dual listing

10 months ago

Schizophrenia biotech LB Pharmaceuticals eyes near-term IPO filing — source

10 months ago

Alumis aims for this year’s third-largest biotech IPO as it readies for Phase 3

10 months ago

Gilead tested an antibody many times. A small biotech salvages it, with $40M and ‘conviction’ elsewhere

10 months ago

iOnctura raises €80M to advance early-stage rare eye cancer treatment

10 months ago

Blank check, please? Three healthcare SPACs reveal their IPO plans

10 months ago

Marea Therapeutics launches with $190M, seeing a 'fixable problem' in a neglected cardiometabolic target

10 months ago

Life sciences investor Decheng Capital targets $700M for fifth fund

11 months ago

Aerovate’s stock craters after PAH drug fails Phase 2 study

11 months ago

Deerfield backs $81M round for biotech developing antifungal therapy with less toxicity

11 months ago

Vaxart wins $453M in BARDA funding for oral Covid-19 vaccine

11 months ago

Stephen Squinto talks writing checks and next-gen obesity drugs as JP Morgan closes first $500M+ biotech fund

11 months ago

AI drug discovery startup goes public in Hong Kong, nabbing $115M to build on pharma partnerships

11 months ago

Updated: Telix Pharmaceuticals pulls Nasdaq listing plans just before trading was to start

11 months ago

'Speed is everything': Versant-backed immunology startup raises $125M with plans for quick data

11 months ago

Exclusive: Former Merck scientists raise $85M to map and drug protein interactions in cancer and autoimmune disease

11 months ago

Foresite Capital closes $900M sixth fund, backing the likes of Xaira and IPO hopeful Alumis

11 months ago

Pivoting to ‘ADC-like’ approach, Versant-backed startup gets $90M Series C

11 months ago

First page Previous page 12 13 141516 17 18 Next page Last page